Literature DB >> 23644820

Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy.

Adriana Malena1, Maria Pennuto, Caterina Tezze, Giorgia Querin, Carla D'Ascenzo, Vincenzo Silani, Giovanna Cenacchi, Annarita Scaramozza, Silvia Romito, Lucia Morandi, Elena Pegoraro, Aaron P Russell, Gianni Sorarù, Lodovica Vergani.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an inherited neuromuscular disease caused by expansion of a polyglutamine (polyQ) tract in the androgen receptor (AR). SBMA is triggered by the interaction between polyQ-AR and its natural ligands, testosterone and dihydrotestosterone (DHT). SBMA is characterized by the loss of lower motor neurons and skeletal muscle fasciculations, weakness, and atrophy. To test the hypothesis that the interaction between polyQ-AR and androgens exerts cell-autonomous toxicity in skeletal muscle, we characterized the process of myogenesis and polyQ-AR expression in DHT-treated satellite cells obtained from SBMA patients and age-matched healthy control subjects. Treatment with androgens increased the size and number of myonuclei in myotubes from control subjects, but not from SBMA patients. Myotubes from SBMA patients had a reduced number of nuclei, suggesting impaired myotube fusion and altered contractile structures. The lack of anabolic effects of androgens on myotubes from SBMA patients was not due to defects in myoblast proliferation, differentiation or apoptosis. DHT treatment of myotubes from SBMA patients increased nuclear accumulation of polyQ-AR and decreased the expression of interleukin-4 (IL-4) when compared to myotubes from control subjects. Following DHT treatment, exposure of myotubes from SBMA patients with IL-4 treatment rescued myonuclear number and size to control levels. This supports the hypothesis that androgens alter the fusion process in SBMA myogenesis. In conclusion, these results provide evidence of an androgen-dependent impairment of myogenesis in SBMA that could contribute to disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644820     DOI: 10.1007/s00401-013-1122-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  26 in total

1.  The first year.

Authors:  Johannes Attems
Journal:  Acta Neuropathol       Date:  2019-12-12       Impact factor: 17.088

2.  Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction.

Authors:  Samir R Nath; Zhigang Yu; Theresa A Gipson; Gregory B Marsh; Eriko Yoshidome; Diane M Robins; Sokol V Todi; David E Housman; Andrew P Lieberman
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

3.  The Expanding Clinical Universe of Polyglutamine Disease.

Authors:  Shanshan Huang; Suiqiang Zhu; Xiao-Jiang Li; Shihua Li
Journal:  Neuroscientist       Date:  2019-01-07       Impact factor: 7.519

4.  Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.

Authors:  Wooi F Lim; Mitra Forouhan; Thomas C Roberts; Jesse Dabney; Ruth Ellerington; Alfina A Speciale; Raquel Manzano; Maria Lieto; Gavinda Sangha; Subhashis Banerjee; Mariana Conceição; Lara Cravo; Annabelle Biscans; Loïc Roux; Naemeh Pourshafie; Christopher Grunseich; Stephanie Duguez; Anastasia Khvorova; Maria Pennuto; Constanza J Cortes; Albert R La Spada; Kenneth H Fischbeck; Matthew J A Wood; Carlo Rinaldi
Journal:  Sci Adv       Date:  2021-08-20       Impact factor: 14.136

Review 5.  In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Manuela Basso
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

Review 6.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

Review 7.  Diagnostic Clinical, Electrodiagnostic and Muscle Pathology Features of Spinal and Bulbar Muscular Atrophy.

Authors:  Manu E Jokela; Bjarne Udd
Journal:  J Mol Neurosci       Date:  2015-11-16       Impact factor: 3.444

Review 8.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

9.  Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations.

Authors:  Michelangelo Cao; Marta Donà; M Lucia Valentino; Lucia Valentino; Claudio Semplicini; Alessandra Maresca; Matteo Cassina; Alessandra Torraco; Eva Galletta; Valeria Manfioli; Gianni Sorarù; Valerio Carelli; Roberto Stramare; Enrico Bertini; Rosalba Carrozzo; Leonardo Salviati; Elena Pegoraro
Journal:  Neurogenetics       Date:  2015-11-10       Impact factor: 2.660

10.  Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients.

Authors:  Claudia Malacarne; Mariarita Galbiati; Eleonora Giagnorio; Paola Cavalcante; Franco Salerno; Francesca Andreetta; Cinza Cagnoli; Michela Taiana; Monica Nizzardo; Stefania Corti; Viviana Pensato; Anna Venerando; Cinzia Gellera; Silvia Fenu; Davide Pareyson; Riccardo Masson; Lorenzo Maggi; Eleonora Dalla Bella; Giuseppe Lauria; Renato Mantegazza; Pia Bernasconi; Angelo Poletti; Silvia Bonanno; Stefania Marcuzzo
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.